RxDoctor Payments DataLook up a doctor →

Timothy Ratino, MD

Interventional Pain Medicine · Fort Worth, TXNPI 1154574044

Payments from drug & device makers

$138,998in general payments, 2019–2025

Across 1,117 payments — averaging $124.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nalu Medical, Inc.$79K
  • Nevro Corp.$39K
  • Globus Medical$9K
  • Spinal Simplicity, LLC$2K
  • Boston Scientific$2K
  • Painteq LLC$1K
  • plus $6K from 38 others

What the payments were for

  • Consulting fees$71,43351%
  • Speaking & faculty fees$20,55015%
  • Travel & lodging$10,3837%
  • Food & beverage$36,48626%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$138,998 in reported general payments places this provider in the 90th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$472,799
Medicare patients
508
Services billed
9,334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen8,239$356,073
Xtampza ErOxycodone Myristate181$75,480
BelbucaBuprenorphine Hcl67$63,559
MovantikNaloxegol Oxalate126$56,229
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,286$50,759
LinzessLinaclotide90$48,253
Morphine Sulfate ErMorphine Sulfate1,089$26,626
Gabapentin2,001$24,425
Oxycodone Hcl1,223$22,925
Tizanidine Hcl1,492$20,555
Aimovig AutoinjectorErenumab-Aooe17$17,730
Lidocaine123$17,490
OxycontinOxycodone Hcl43$17,304
Pregabalin717$16,368
Buprenorphine60$13,831

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$147$139,040248 claims
Redhill Biopharma Inc.Movantik$30$56,229126 claims
AbbVieLinzess$801$48,25390 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →